29 January 2025

Chair, Pharmaceutical Benefits Advisory Committee (PBAC)
Department of Health and Ageing
GPO Box 9848 Canberra ACT 2601

Dear PBAC Chair,

RE: PBS listing of a new strength of Xolair® (omalizumab)

We are writing on behalf of the National Allergy Council and Allergy & Anaphylaxis Australia, in support of the request by Novartis Pharmaceuticals Australia Pty Ltd for the Pharmaceutical Benefits Scheme (PBS) listing of a new strength of Xolair® (omalizumab)as follows:

> *To request Section 100 (Highly Specialised Drugs Program) Authority Required listings of a new strength and new forms of omalizumab for the treatment of uncontrolled severe asthma, uncontrolled severe allergic asthma, and severe chronic spontaneous urticaria for: Omalizumab (Xolair®) Injection 75 mg in 0.5 mL single dose pre-filled syringe; Injection 150 mg in 1 mL single dose pre-filled syringe; Injection 300 mg in 2 mL single dose pre-filled syringe; Injection 75 mg in 0.5 mL single dose pre-filled pen; Injection 150 mg in 1 mL single dose pre-filled pen; Injection 300 mg in 2 mL single dose pre-filled pen for: Uncontrolled severe asthma; Uncontrolled severe allergic asthma; Severe chronic spontaneous urticaria.*

We support this request to ensure equitable access to Omalizumab (Xolair®), a medication which is one of the most effective treatments for Chronic Spontaneous Urticaria (CSU), in addition to uncontrolled severe asthma and uncontrolled severe allergic asthma. Multiple dose availability supports appropriate dosing and can help reduce supply issues.

Kind regards,

Ms Maria Said AM
CEO
Allergy & Anaphylaxis Australia

Dr Sandra Vale
CEO
National Allergy Council